It predicts response to immunotherapy and can detect Lynch syndrome — yet in France, many patients still miss out.
Why?
Because high-performance NGS panels for MSI aren’t consistently or fully reimbursed.
- HAS has supported adding targeted NGS panels to the NABM, but coverage remains partial and varies by indication.
- RIHN (temporary innovation funding) often covers only ~50% of costs — and only for a limited period — leaving labs to absorb the rest.
- Many hospitals still rely on PCR, which is reimbursed but can miss MSI in up to 40% of tumors outside colorectal cancer.
- NGS offers higher accuracy and pan-cancer utility, but without full tariffing, adoption remains limited.
The result?
❌ Missed Lynch syndrome diagnoses
❌ Lost or delayed access to immunotherapy
❌ Inequitable access to precision oncology
At MSInsight, we believe precision diagnostics must be accessible. It’s time for France to make NGS-based MSI testing standard and fully reimbursable — so every patient benefits from the best available science.
